PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31061066-0	2019	Targeting the High-Mobility Group Box 3 Protein Sensitizes Chemoresistant Ovarian Cancer Cells to Cisplatin.	Cisplatin	98-107	high mobility group box 3	Homo sapiens	14-39	
31061066-3	2019	In this study, we report that cisplatin sensitivity can be restored in cisplatin-resistant ovarian cancer cells by targeting the chromatin-associated high-mobility group box 3 (HMGB3) protein.	Cisplatin	30-39	high mobility group box 3	Homo sapiens	150-175	
31061066-3	2019	In this study, we report that cisplatin sensitivity can be restored in cisplatin-resistant ovarian cancer cells by targeting the chromatin-associated high-mobility group box 3 (HMGB3) protein.	Cisplatin	30-39	high mobility group box 3	Homo sapiens	177-182	
31061066-3	2019	In this study, we report that cisplatin sensitivity can be restored in cisplatin-resistant ovarian cancer cells by targeting the chromatin-associated high-mobility group box 3 (HMGB3) protein.	Cisplatin	71-80	high mobility group box 3	Homo sapiens	150-175	
31061066-3	2019	In this study, we report that cisplatin sensitivity can be restored in cisplatin-resistant ovarian cancer cells by targeting the chromatin-associated high-mobility group box 3 (HMGB3) protein.	Cisplatin	71-80	high mobility group box 3	Homo sapiens	177-182	
31061066-5	2019	Depletion of HMGB3 in cisplatin-sensitive and cisplatin-resistant cells resulted in transcriptional downregulation of the kinases ATR and CHK1, which attenuated the ATR/CHK1/p-CHK1 DNA damage signaling pathway.	Cisplatin	22-31	high mobility group box 3	Homo sapiens	13-18	
31061066-5	2019	Depletion of HMGB3 in cisplatin-sensitive and cisplatin-resistant cells resulted in transcriptional downregulation of the kinases ATR and CHK1, which attenuated the ATR/CHK1/p-CHK1 DNA damage signaling pathway.	Cisplatin	46-55	high mobility group box 3	Homo sapiens	13-18	
31061066-7	2019	Furthermore, HMGB3 depletion significantly increased apoptosis in cisplatin-resistant A2780/CP70 cells after cisplatin treatment.	Cisplatin	66-75	high mobility group box 3	Homo sapiens	13-18	
31061066-7	2019	Furthermore, HMGB3 depletion significantly increased apoptosis in cisplatin-resistant A2780/CP70 cells after cisplatin treatment.	Cisplatin	109-118	high mobility group box 3	Homo sapiens	13-18	
31061066-8	2019	Taken together, our results indicate that targeted depletion of HMGB3 attenuates cisplatin resistance in human ovarian cancer cells, increasing tumor cell sensitivity to platinum drugs.	Cisplatin	81-90	high mobility group box 3	Homo sapiens	64-69	
27774979-12	2016	Silencing of HMGB3 enhanced sensitive to cisplatin and paclitaxel, and reduced sensitive to oxaliplatin.	Cisplatin	41-50	high mobility group box 3	Homo sapiens	13-18